Patients in landmark genome-editing trial show improvement — but questions linger

Patients in landmark genome-editing trial show improvement — but questions linger

STAT Plus: Patients in landmark genome-editing trial show improvement — but with questions over whether the therapy did the trick

By ADAM FEUERSTEIN

ALEX HOGAN/STAT

While patients showed improvement, Sangamo is downplaying some results from the study that are confounding and may give outsiders reason to be concerned.

READ MORE